Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)

• Main Authors: Alessandro D. Santin (Author), Virginia Filiaci (Author), Stefania Bellone (Author), Elena S. Ratner (Author), Cara A. Mathews (Author), Guilherme Cantuaria (Author), Camille C. Gunderson (Author), Teresa Rutledge (Author), Barbara M. Buttin (Author), Heather A. Lankes (Author), Michael Frumovitz (Author), Samir N. Khleif (Author), Warner K. Huh (Author), Michael J. Birrer (Author)
• Format: Book
• Published: Elsevier, 2020-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Purpose: NRG Oncology conducted a phase II trial to assess the antitumor activity and tolerability of copanlisib, a selective inhibitor of PIK3CA, in persistent or recurrent endometrial carcinoma harboring hotspot PIK3CA mutations. Patients and methods: Eligible patients had endometrial cancer with...